Norveç - Norveççe - Statens legemiddelverk

abacus medicine a/s - venetoklaks - tablett, filmdrasjert - 50 mg

Norveç - Norveççe - Statens legemiddelverk

abacus medicine a/s - venetoklaks - tablett, filmdrasjert - 100 mg

Avrupa Birliği - Norveççe - EMA (European Medicines Agency)

pfizer europe ma eeig  - palbociclib - bryst neoplasms - antineoplastiske midler - ibrance er angitt for behandling av hormon-reseptor (hr) positiv, human epidermal vekstfaktor reseptor 2 (her2) negative lokalt avansert eller metastatisk brystkreft:i kombinasjon med en aromatasehemmer, i kombinasjon med fulvestrant i kvinner som har fått før endokrin terapi. i pre - eller perimenopausal women, endokrin terapi bør kombineres med en luteiniserende hormon-frigjørende hormon (lhrh) agonist.

Avrupa Birliği - Norveççe - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - venetoclax - leukemi, lymfocytisk, kronisk, b-celle - antineoplastiske midler - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly  diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.

Avrupa Birliği - Norveççe - EMA (European Medicines Agency)

takeda pharma a/s - brigatinib - karsinom, ikke-småcellet lunge - antineoplastiske midler - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.

Avrupa Birliği - Norveççe - EMA (European Medicines Agency)

merck sharp & dohme b.v. - doravirine - hiv-infeksjoner - antivirale midler til systemisk bruk - pifeltro is indicated, in combination with other antiretroviral medicinal products, for the treatment of adults, and adolescents aged 12 years and older weighing at least 35 kg infected with hiv 1 without past or present evidence of resistance to the nnrti class.

Avrupa Birliği - Norveççe - EMA (European Medicines Agency)

secura bio limited - duvelisib - leukemia, lymphocytic, chronic, b-cell; lymphoma, follicular - antineoplastiske midler - copiktra monotherapy is indicated for the treatment of adult patients with: relapsed or refractory chronic lymphocytic leukaemia (cll) after at least two prior therapies.  follicular lymphoma (fl) that is refractory to at least two prior  systemic therapies.

Norveç - Norveççe - Statens legemiddelverk

abacus medicine a/s - doravirin - tablett, filmdrasjert - 100 mg